Table 1 Summary of patients with epithelioid hemangioendothelioma treated with anti-angiogenic therapy
First author (ref) | No.pts. | Median age | Gender | Treatment medications | Response |
|---|---|---|---|---|---|
Gaur S [6] | 1 | 35 | M | Bevacizumab, Nab-Paclitaxel | SD |
Belmont [22] | 1 | 41 | M | Bevacizumab, Carboplatin, Paclitaxel | PR |
Kim [15] | 1 | 44 | F | Bevacizumab, Carboplatin, Paclitaxel | PD |
Lopes [16] | 1 | 51 | M | Bevacizumab, Carboplatin, Etoposide | PD |
Mizota [23] | 1 | 59 | F | Bevacizumab, Carboplatin, Paclitaxel | PD |
Ye [9] | 1 | 44 | F | Bevacizumab, Carboplatin, Paclitaxel | SD |
Lazarus [24] | 1 | 42 | M | Bevacizumab, Paclitaxel | PD |
1 | 42 | M | Carboplatin, Etoposide | PD | |
Salech [25] | 1 | 40 | F | Thalidomide | PR |
Raphael et al. [26] | 1 | 53 | F | Thalidomide | SD |
Kassam et al. [27] | 1 | 13 | F | Thalidomide | PD |
Bolke et al. [28] | 1 | 47 | M | Thalidomide | PD |
Mascarenhas et al. [29] | 1 | 52 | M | Thalidomide | PR |
Pallotti et al. [31] | 1 | 73 | M | Lenalidomide | SD |
Sumrall et al. [30] | 1 | 31 | F | Lenalidomide | SD |
Agulnik et al. [18] | 2 | NA | NA | Bevacizumab | PR |
1 | NA | NA | Bevacizumab | PD | |
4 | NA | NA | Bevacizumab | SD | |
Chevreau et al. [19] | 5 | NA | NA | Sorafenib | SD |
2 | NA | NA | Sorafenib | PR | |
8 | NA | NA | Sorafenib | PD |